Guselkumab Intravenous

Phase 3

Johnson & Johnson

Guselkumab Intravenous is one of 18 therapeutic programs targeting Colitis, Ulcerative. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Colitis, UlcerativeActive, not recruiting

Colitis, UlcerativePhase 3

Active, not recruiting

Competition

Competitive Landscape

20 competitors in Colitis, Ulcerative

#DrugCompanyPhaseTrials

Tremfya

Johnson & Johnson

Phase 3

4 2

Simponi

Johnson & Johnson

Phase 3

2 3

Icotyde

Johnson & Johnson

Phase 3

1 4

Remicade

OOrganon and Co

Phase 3

1 5

Velsipity

Pfizer

Phase 2

3 6

JNJ-78934804

Johnson & Johnson

Phase 3

2 7

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Phase 2

1 8

Guselkumab Dose 3

Johnson & Johnson

Phase 3

1 9

Guselkumab Dose 1

Johnson & Johnson

Phase 3

1 10

Guselkumab Dose 2

Johnson & Johnson

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Active, not recruiting

Colitis, Ulcerative

NCT06260163

Clinical

Trials by Indication[1]

Colitis, Ulcerative1 trial

A Phase 3 Randomized, Open-label Induction, Double-blind Maintenance, Parallel-group, Multicenter Protocol to Evaluate the Efficacy, Safety, and Pharmacokinetics of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT06260163·112 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Guselkumab Intravenous. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Guselkumab Intravenous. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Johnson & Johnson

Guselkumab Intravenous

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Colitis, Ulcerative1 trial

References

Drug Info

Quick Facts

Related News